
Ex Vivo Lung Perfusion (EVLP) - Penn Medicine
Ex vivo lung perfusion (EVLP) is an innovative therapy applied to donor lungs outside of the body before transplantation that improves organ quality and makes lungs that were previously …
EABR 插入到 Spike 蛋白胞质尾部,导致 eVLP 的出芽和释放。 - 知乎
目前,常规的用于生成 eVLP 的方法,一个是采用抗原与病毒与病毒衣壳蛋白共表达来生成 eVLP ,另外一个是Tag/Catcher 技术,基本原理是选择镶嵌 Catcher 序列的蛋白纳米颗粒作为骨 …
Engineered virus-like particles for transient delivery of ... - Nature
2024年1月8日 · Here we report prime editor engineered virus-like particles (PE-eVLPs) that deliver prime editor proteins, prime editing guide RNAs and nicking single guide RNAs as …
浅谈体外肺灌注技术优化供肺的实践与思考 - 中华器官移植杂志
体外肺灌注 (ex vivo lung perfusion,EVLP)技术是在体外模拟肺通气及循环灌注状态对供肺进行评估和修复的工具,可以帮助改善供肺功能,使部分边缘供肺达到移植标准,从而增加边缘供肺 …
Ex-Vivo Lung Perfusion Therapies: Do They Add Value to Organ …
EVLP is a promising technology with the potential to address many of shortcomings of traditional organ donation. On-going research in the capabilities of EVLP to recondition injured lungs, …
Ex Vivo Lung Perfusion: A Review of Current and Future …
Ex vivo lung perfusion (EVLP) is a rapidly developing and increasingly utilized technology to increase the lung donor pool for transplantation. EVLP has evolved into a device for logistical …
Ex vivo lung perfusion - PMC
Among potential alternatives to address this issue, ex vivo lung perfusion (EVLP) has emerged as a modern preservation technique that allows for more accurate lung assessment and also …
Ex Vivo Lung Perfusion - CHEST
2017年2月23日 · Ex vivo lung perfusion (EVLP) promises to be a comprehensive platform for assessment, reconditioning, and preservation of donor lungs and has been dramatically …
Ex Vivo Lung Perfusion (EVLP) for Lung Transplantation
What is EVLP? EVLP is an innovative therapy. It is applied to donor lungs outside of the body before they are transplanted. It improves organ quality. It also makes lungs safe for transplant …
Engineered virus-like particles for efficient in vivo delivery of ...
2022年1月11日 · Methods to deliver gene editing agents in vivo as ribonucleoproteins could offer safety advantages over nucleic acid delivery approaches. We report the development and …